Orthofix International N.V. (OFIX) Shares Sold by Principal Financial Group Inc.
Principal Financial Group Inc. reduced its holdings in shares of Orthofix International N.V. (NASDAQ:OFIX) by 1.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 137,777 shares of the medical device company’s stock after selling 2,690 shares during the quarter. Principal Financial Group Inc. owned approximately 0.76% of Orthofix International N.V. worth $6,404,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also modified their holdings of the company. Paradice Investment Management LLC bought a new position in shares of Orthofix International N.V. during the 2nd quarter worth approximately $6,642,000. River Road Asset Management LLC bought a new stake in Orthofix International N.V. in the 2nd quarter valued at $6,419,000. Balter Liquid Alternatives LLC bought a new stake in Orthofix International N.V. in the 2nd quarter valued at $483,000. Victory Capital Management Inc. boosted its stake in Orthofix International N.V. by 1.2% in the 2nd quarter. Victory Capital Management Inc. now owns 32,089 shares of the medical device company’s stock valued at $1,491,000 after purchasing an additional 365 shares during the period. Finally, Federated Investors Inc. PA boosted its stake in Orthofix International N.V. by 4.9% in the 2nd quarter. Federated Investors Inc. PA now owns 114,834 shares of the medical device company’s stock valued at $5,337,000 after purchasing an additional 5,392 shares during the period. Institutional investors own 94.40% of the company’s stock.
In other Orthofix International N.V. news, CFO Rice Doug sold 7,353 shares of Orthofix International N.V. stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $49.46, for a total transaction of $363,679.38. Following the sale, the chief financial officer now directly owns 44,743 shares of the company’s stock, valued at approximately $2,212,988.78. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Brad Mason sold 2,733 shares of Orthofix International N.V. stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $48.10, for a total value of $131,457.30. Following the sale, the chief executive officer now directly owns 188,053 shares in the company, valued at $9,045,349.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,406 shares of company stock worth $1,138,531. Insiders own 5.60% of the company’s stock.
Shares of Orthofix International N.V. (OFIX) opened at 47.25 on Friday. The company’s 50 day moving average price is $47.80 and its 200 day moving average price is $43.18. Orthofix International N.V. has a 12 month low of $32.51 and a 12 month high of $50.40. The company has a market cap of $858.53 million, a price-to-earnings ratio of 110.66 and a beta of 0.22.
Orthofix International N.V. (NASDAQ:OFIX) last announced its quarterly earnings results on Monday, August 7th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. Orthofix International N.V. had a return on equity of 9.96% and a net margin of 1.88%. The company had revenue of $108.90 million for the quarter, compared to the consensus estimate of $102.94 million. During the same quarter in the previous year, the business earned $0.41 EPS. Orthofix International N.V.’s revenue was up 4.6% compared to the same quarter last year. On average, equities analysts expect that Orthofix International N.V. will post $1.56 EPS for the current fiscal year.
Several analysts recently issued reports on the company. Zacks Investment Research upgraded Orthofix International N.V. from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research note on Thursday, August 10th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $55.00 price objective (up from $50.00) on shares of Orthofix International N.V. in a report on Thursday, August 10th. TheStreet raised Orthofix International N.V. from a “c+” rating to a “b-” rating in a report on Tuesday, August 8th. BidaskClub raised Orthofix International N.V. from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Finally, Langenberg & Company reissued a “buy” rating and set a $53.25 price target on shares of Orthofix International N.V. in a report on Wednesday, June 14th. Seven equities research analysts have rated the stock with a buy rating, Orthofix International N.V. has an average rating of “Buy” and an average price target of $52.75.
Orthofix International N.V. Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Stock Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related stocks with our FREE daily email newsletter.